{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:15:26Z","timestamp":1773342926478,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["21JR1RA146"],"award-info":[{"award-number":["21JR1RA146"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lanzhou University Second Hospital \u201cCuiying Technology Innovation\u201d Program","award":["CY2018-BJ17"],"award-info":[{"award-number":["CY2018-BJ17"]}]},{"name":"Lanzhou University Second Hospital \u201cCuiying Technology Innovation\u201d Program","award":["CY2021-QN-A18"],"award-info":[{"award-number":["CY2021-QN-A18"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy and safety of tenofovir alafenamide fumarate (TAF) in nucleos(t)ide analogue (NA)-experienced patients with chronic hepatitis B (CHB) who exhibited partial virological response (PRT) or low-level viremia (LLV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective, real-world study enrolled NA-experienced CHB patients who were switched to TAF treatment. Patients were categorized into the PRT (HBV DNA &amp;gt; 2,000 IU\/mL) or LLV (20 IU\/ mL &amp;lt; HBV DNA \u2264 2,000 IU\/mL) groups according to baseline HBV DNA levels. The dynamic changes in HBV DNA, HBsAg, HBeAg, ALT, and APRI were analyzed after switching to TAF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 91 CHB patients with prior NA treatment and detectable HBV DNA after at least 48 weeks of therapy were enrolled and subsequently switched to TAF. Among them, 24 patients had PRT, and 67 patients had LLV. The complete virological response rate (HBV DNA &amp;lt; 20 IU\/mL) in the PRT group was 29.1% at week 24 and 75.0% at week 48; in the LLV group, it was 76.1% and 88.1%, respectively. Both groups showed a decline in HBeAg levels from baseline to week 24 and 48. In the PRT group, HBsAg levels decreased by 9.0% and 5.0% at week 24 and 48, respectively; in the LLV group, the reductions were 2.1% and 3.6%. The ALT normalization rate increased by 24.2% at week 48 compared with baseline. Additionally, eGFR levels improved after switching to TAF. No serious adverse events (SAEs) or deaths related to adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study suggests that switching to TAF is an effective and well-tolerated therapeutic strategy for NA-experienced CHB patients with PRT or LLV, offering a promising approach for treatment optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1592998","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:21:51Z","timestamp":1763101311000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"ref1","article-title":"Global hepatitis report, 2017","year":"2017"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","article-title":"Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years","volume":"35","author":"Wong","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2014","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3350\/cmh.2020.0121","article-title":"How does low-level viremia affect the prognosis of patients with chronic hepatitis B?","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/jac\/dku502","article-title":"Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study","volume":"70","author":"Maggi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.14218\/JCTH.2021.00209","article-title":"Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for prevention and treatment of chronic hepatitis B.","volume":"9","author":"Wang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Uchida","year":"2019","journal-title":"J Med Virol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/s0168-8278(17)30313-6","article-title":"A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96","volume":"66","author":"Brunetto","year":"2017","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","author":"Kaneko","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3969\/j.issn.1672-5069.2022.05.007","article-title":"Different switching strategies in nucleos(t)ide analogue\u2013experienced chronic hepatitis B patients with low-level viremia: a single-center retrospective study","volume":"25","author":"Liu","year":"2022","journal-title":"J Prac Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1592998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:21:53Z","timestamp":1763101313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1592998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":25,"alternative-id":["10.3389\/fmed.2025.1592998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1592998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1592998"}}